Fujifilm diosynth biotechnologies and regeneron sign a 10-year u.s. manufacturing agreement valued at over $3 billion

Holly springs, n.c.--(business wire)-- #stemcells--fujifilm diosynth biotechnologies, a world-leading contract development and manufacturing organization (cdmo) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion, with regeneron pharmaceuticals, inc. (nasdaq: regn) to provide u.s.-based production of its industry-leading biologic medicines, which treat millions of patients worldwide. under the terms of the agreement, fujifilm d.
REGN Ratings Summary
REGN Quant Ranking